News - Men's Health, Eisai

Filter

Current filters:

Men's HealthEisai

Popular Filters

1 to 25 of 167 results

Ampio’s Vyrix unit out-licenses certain rights for Zertane to Paladin

10-04-2014

USA-based biotech firm Ampio Pharmaceuticals says its wholly-owned subsidiary Vyrix Pharmaceuticals…

Ampio PharmaceuticalsBiotechnologyEndo Health SolutionsLicensingMen's HealthPaladin LabsVyrix PharmaceuticalsZertane

Otsuka acquires certain Dacogen and E7727 rights from Eisai

01-04-2014

Otsuka Pharmaceutical has reached an agreement with the US subsidiary of fellow Japanese drugmaker Eisai…

DacogenE7727EisaiLicensingOncologyOtsukaPharmaceutical

Japan’s Eisai joins forces with UK researchers on tropical disease research

Japan’s Eisai joins forces with UK researchers on tropical disease research

20-03-2014

Japanese drug major Eisai has entered a collaboration with the UK’s Liverpool School of Tropical Medicine…

EisaiPharmaceuticalResearchTropical diseases

Pfizer tackles Torrent over generic Viagra

Pfizer tackles Torrent over generic Viagra

19-03-2014

US pharma giant Pfizer is taking legal action against Indian drugmaker Torrent Pharmaceuticals to stop…

GenericsIndiaLegalMen's HealthPfizerPharmaceuticalTorrent PharmaceuticalsUSAViagra

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Endo’s testosterone replacement Aveed gets FDA approval

Endo’s testosterone replacement Aveed gets FDA approval

06-03-2014

Endo International says its operating company Endo Pharmaceuticals has received US Food and Drug Administration…

AveedEndo PharmaceuticalsMen's HealthNorth AmericaPharmaceuticalRegulationUSA

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

05-03-2014

US biotech firm Biogen Idec and Japanese drugmaker Eisai have entered into a collaboration to develop…

BAN2401BIIB037Biogen IdecBiotechnologyE2609EisaiLicensingNeurologicalResearch

Recordati gains certain rights to Apricus’ Vitaros

10-02-2014

Italian drugmaker Recordati has signed an exclusive license agreement with the USA’s Apricus Biosciences…

Apricus BioscienceEastern EuropeLicensingMen's HealthPharmaceuticalRecordatiRest of the WorldTurkeyVitaros

Eisai’s lenvatinib meets primary endpoint in Ph III thyroid cancer study

Eisai’s lenvatinib meets primary endpoint in Ph III thyroid cancer study

03-02-2014

Japanese drug major Eisai says that the Phase III SELECT trial (Study 303) of lenvatinib, an investigational…

EisailenvatinibOncologyPharmaceuticalResearch

FDA investigating risk of stroke, heart attack and death with testosterone products

FDA investigating risk of stroke, heart attack and death with testosterone products

03-02-2014

The US Food and Drug Administration said on Friday that it is investigating the risk of stroke, heart…

AbbVieActavisAndrodermAndroGelAxironEli LillyMen's HealthNorth AmericaPharmaceuticalRegulationResearchTestosteroneUSA

Eisai’s amatuximab gains orphan status in EU for malignant mesothelioma

Eisai’s amatuximab gains orphan status in EU for malignant mesothelioma

22-01-2014

The investigational monoclonal antibody amatuximab (development code: MORAb-009), has today been granted…

amatuximabEisaiEuropePharmaceuticalRare diseasesRegulation

Ranbaxy cleared to market branded generic of Aricept in Canada

Ranbaxy cleared to market branded generic of Aricept in Canada

08-01-2014

The Canadian subsidiary of Ranbaxy Laboratories has received approval to manufacture and market RAN-Donepezil…

AriceptCanadaDaiichi SankyoEisaiGenericsNeurologicalNorth AmericaRAN-DonepezilRanbaxy LaboratoriesRegulation

Eisai’s epilepsy drug Fycompa to launch in USA

Eisai’s epilepsy drug Fycompa to launch in USA

02-01-2014

The US subsidiary of Japanese pharma major Eisai’s that its epilepsy drug Fycompa (perampanel) will…

EisaiFycompaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalUSA

Ampio Pharma takes spin-out route on failure to find Zertane partner

Ampio Pharma takes spin-out route on failure to find Zertane partner

16-12-2013

US drug developer Ampio Pharmaceuticals announced that it has spun off its sexual dysfunction business…

Ampio PharmaceuticalsAmpionInflammatory diseasesMen's HealthMergers & AcquisitionsPharmaceuticalProductionVyrix PharmaceuticalsZertane

Apricus expands Vitaros deal with Novartis unit

Apricus expands Vitaros deal with Novartis unit

16-12-2013

USA-based Apricus Biosciences has expanded its exclusive license agreement with Hexal AG, an affiliate…

Apricus BioscienceEuropeLicensingMen's HealthNovartisPharmaceuticalSandozVitaros

Sanofi to commercialize Vivus ED drug in Africa, Middle East, Turkey and CIS/Russia

Sanofi to commercialize Vivus ED drug in Africa, Middle East, Turkey and CIS/Russia

12-12-2013

US drugmaker Vivus has entered into a license and commercialization agreement with French pharma major…

avanafilEastern EuropeLicensingMarkets & MarketingMen's HealthPharmaceuticalRest of the WorldSanofiVivus

Increase in awareness of hypogonadism will drive testosterone replacement therapy market

11-12-2013

The testosterone replacement therapy (TRT) market has been forecast to reach a value of $5.1 billion…

GlobalMarkets & MarketingMen's HealthPharmaceutical

UK Dementia Consortium to bridge the gap between academia and pharma

UK Dementia Consortium to bridge the gap between academia and pharma

11-12-2013

The UK has today announced a new £3 million ($4.9 million) Dementia Consortium bringing together research…

EisaiEli LillyNeurologicalPharmaceuticalPoliticsResearchUK

US FDA approves first drug treatment for Peyronie’s disease

US FDA approves first drug treatment for Peyronie’s disease

07-12-2013

The US Food and Drug Administration has approved a new use for US company Auxilium Pharmaceuticals Xiaflex…

Auxilium PharmaceuticalsMen's HealthNorth AmericaPharmaceuticalRegulationXiaflex

Eisai’s R&D organization undergoes “transformation”

Eisai’s R&D organization undergoes “transformation”

30-11-2013

Japanese drugmaker Eisai's president and chief executive, Haruo Naito, says that the company's R&D organization,…

Asia-PacificEisaiEuropeManagementNorth AmericaPharmaceuticalResearchUSA

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

25-11-2013

Japanese drug major Eisai (TYO: 4523) will become the Marketing Authorization Holder for the antineoplastic…

Antibiotics and Infectious diseasesAsia-PacificEisaiGliadelLicensingNobelpharmaOncologyPharmaceutical

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

20-11-2013

Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

1 to 25 of 167 results

Back to top